Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 17,858 Shares

by · The Cerbat Gem

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) Director Luke Evnin sold 17,858 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $1.08, for a total transaction of $19,286.64. Following the completion of the transaction, the director directly owned 2,890,128 shares of the company’s stock, valued at approximately $3,121,338.24. The trade was a 0.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Luke Evnin also recently made the following trade(s):

  • On Thursday, December 11th, Luke Evnin sold 28,009 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.07, for a total transaction of $29,969.63.
  • On Wednesday, December 10th, Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.06, for a total transaction of $39,330.24.
  • On Tuesday, December 9th, Luke Evnin sold 44,570 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.01, for a total transaction of $45,015.70.
  • On Monday, December 8th, Luke Evnin sold 34,041 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.99, for a total transaction of $33,700.59.
  • On Friday, December 5th, Luke Evnin sold 16,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.97, for a total value of $16,070.96.
  • On Thursday, December 4th, Luke Evnin sold 53,416 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.97, for a total value of $51,813.52.
  • On Wednesday, December 3rd, Luke Evnin sold 36,726 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.87, for a total value of $31,951.62.
  • On Tuesday, December 2nd, Luke Evnin sold 38,043 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.89, for a total value of $33,858.27.
  • On Monday, December 1st, Luke Evnin sold 39,096 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total value of $36,750.24.
  • On Friday, November 28th, Luke Evnin sold 13,014 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.99, for a total value of $12,883.86.

Werewolf Therapeutics Stock Up 0.9%

Shares of Werewolf Therapeutics stock traded up $0.01 on Friday, reaching $1.10. 368,752 shares of the company were exchanged, compared to its average volume of 501,947. The stock’s 50 day moving average price is $1.30 and its 200-day moving average price is $1.33. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 3.87. Werewolf Therapeutics, Inc. has a 1-year low of $0.60 and a 1-year high of $2.38. The company has a market cap of $53.39 million, a P/E ratio of -0.68 and a beta of 0.74.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last issued its earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.03. As a group, equities analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on HOWL. JMP Securities reduced their price objective on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a report on Thursday, August 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Bank of America decreased their price target on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Zacks Research downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. Finally, Citigroup reissued a “market outperform” rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.75.

View Our Latest Report on Werewolf Therapeutics

Hedge Funds Weigh In On Werewolf Therapeutics

Several large investors have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. grew its holdings in shares of Werewolf Therapeutics by 33.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock worth $93,000 after purchasing an additional 23,852 shares during the last quarter. MPM Asset Management LLC lifted its holdings in shares of Werewolf Therapeutics by 0.6% in the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after purchasing an additional 25,688 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of Werewolf Therapeutics in the 2nd quarter valued at about $92,000. Nuveen LLC acquired a new stake in shares of Werewolf Therapeutics in the 1st quarter valued at about $71,000. Finally, MPM Bioimpact LLC grew its stake in Werewolf Therapeutics by 0.9% during the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock worth $2,341,000 after buying an additional 20,799 shares during the last quarter. Institutional investors and hedge funds own 64.84% of the company’s stock.

About Werewolf Therapeutics

(Get Free Report)

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.

See Also